Inhibitory effects of tiotropium on rhinovirus infection in human airway epithelial cells

by

Mutsuo Yamaya,1 Hidekazu Nishimura,2 Yukimasa Hatachi,3 Hiroyasu Yasuda,4 Xue Deng,4 Takahiko Sasaki,5 Hiroshi Kubo,1 Ryoichi Nagatomi6

1Department of Advanced Preventive Medicine for Infectious Disease, Tohoku University School of Medicine, 2Virus Research Center, Clinical Research Division, Sendai National Hospital, Sendai 983-8520, 3Department of Respiratory Medicine, Graduate School of Medicine Kyoto University, Kyoto 606-8507, 4Department of Innovation of New Biomedical Engineering Center, Tohoku University, 980-8574, 5Department of Respiratory Medicine, Tohoku University School of Medicine, 980-8574, and 6Medicine and Science in Sports and Exercise, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan

Running head: Tiotropium and rhinovirus infection
Send correspondence to: Mutsuo Yamaya, MD, PhD
Professor and Chairman
Department of Advanced Preventive Medicine for Infectious Disease,
Tohoku University Graduate School of Medicine,
2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan
TEL: 81-22-717-7182
FAX: 81-22-717-7576
E-mail: myamaya@med.tohoku.ac.jp

Copyright 2012 by the European Respiratory Society.
ABSTRACT

Infection by rhinoviruses (RVs) causes exacerbations of chronic obstructive pulmonary disease (COPD). The long-acting anti-cholinergic agent tiotropium reduces the frequency of COPD exacerbations, but the inhibitory effects of tiotropium on the COPD exacerbations induced by RVs are unclear. Likewise, the effects of tiotropium on RVs infection remain to be studied.

To examine the effects of tiotropium on RV infection and RV infection-induced airway inflammation, human tracheal epithelial cells were infected with a major group RV, type 14 rhinovirus (RV14).

RV14 infection increased the viral titer and the amount of pro-inflammatory cytokines, including interleukin (IL)-1β and IL-6, in supernatant fluids and the amount of RV14 RNA in cells. Tiotropium reduced RV14 titers, RNA and cytokine concentrations, and susceptibility to RV14 infection. Tiotropium reduced the expression of intercellular adhesion molecule-1 (ICAM-1), the receptor for RV14, and the number of cellular acidic endosomes, which allow RV14 RNA to enter the cytoplasm. Tiotropium inhibited the activation of nuclear factor kappa-B proteins, including p50 and p65, in the nuclear extracts, and it increased the cytosolic amount of inhibitory kappa-B-α.

Tiotropium may inhibit RV14 infection by reducing the levels of ICAM-1 and acidic endosomes and may also modulate airway inflammation in rhinovirus infection.

Key words: airway epithelial cell; inflammatory cytokine; intercellular adhesion molecule; rhinovirus
INTRODUCTION

The long-acting anti-cholinergic agent tiotropium improves symptoms and lung function in patients with chronic obstructive pulmonary disease (COPD) [1]. In addition, tiotropium reduces the frequency of exacerbations in patients with COPD [1]. These clinical benefits of tiotropium may be related to various effects of the agent, including bronchodilating effects [1], the reduction of airway smooth muscle hypertrophy, and the inhibition of mucus hypersecretion and goblet cell metaplasia [2].

Rhinoviruses (RVs) are the main cause of the common cold, and they are also responsible for the most common acute infection illnesses in humans [3]. In addition, RVs are associated with exacerbations of inflammatory chronic pulmonary diseases, such as COPD [4]. Several mechanisms of RV-induced exacerbations of these diseases have been proposed, including virus-induced mucus hypersecretion, airway inflammation [4], and smooth muscle contraction. RV infection induces the production of cytokines and monokines, including interleukin-1 (IL-1), IL-6, and IL-8 [5, 6]. These cytokines and monokines have pro-inflammatory effects [4, 7], and they may also be involved in the pathogenesis of RV infections and infection-induced COPD exacerbations. Tiotropium inhibits the production of pro-inflammatory cytokines and monokines, including IL-6 in mouse lungs, and reduces the number of neutrophils in bronchoalveolar lavage fluids in a mouse model of COPD [7]. However, tiotropium does not reduce sputum IL-6 levels in COPD patients [8]. Thus, the inhibitory effects of tiotropium on airway inflammation have not been well-studied.

The major group of RVs enters the cytoplasm of infected cells after binding to the receptor known as intercellular adhesion molecule (ICAM)-1 [9, 10]. The entry of the RNA from this group into the cytoplasm of infected cells has been suggested to be mediated by destabilization due to receptor binding and by endosomal acidification [9]. A variety of agents, including glucocorticoids, the macrolide antibiotics bafilomycin and
erythromycin, the proton pump inhibitor lansoprazole, and the β2 agonist procaterol inhibit infection by the major group of RVs by reducing ICAM-1 expression or by increasing endosomal pH [11-13]. Tiotropium has been reported to reduce ICAM-1 expression in the hepatocellular cell line, Hep2 [14], and is partially related to the inhibition of respiratory syncytial virus infection. However, the inhibitory effects of tiotropium on RV infection are unclear.

We studied the effects of a long-acting anti-cholinergic agent, tiotropium, on RV infection in primary cultures of human tracheal epithelial cells. We also examined the effects of tiotropium on the production of ICAM-1 and on endosomal pH to clarify the mechanisms responsible for the inhibition of RV infection.

MATERIALS AND METHODS

**Human tracheal epithelial cell culture**

Human tracheal surface epithelial cells were isolated and cultured as described previously [6]. The cells were plated at 5 x 10^5 viable cells/ml in plastic tubes with round bottoms (Becton Dickinson, Franklin Lakes, NJ, USA). The tubes were kept stationary, and the cells were immersed in 1 ml of Dulbecco’s modified Eagle’s Medium (DMEM)–Ham’s F-12 medium (50/50, vol/vol) containing 2% ultroser G (USG; Pall BioSep, Cergy-Saint-Christophe, France), and they were then cultured at 37°C in 5% CO₂–95% air in the incubator.

To enhance RV14 release from the cells, cells were cultured in tubes by rolling [3, 6]. Therefore, to study the effects of tiotropium on the release of RV and cytokines, RV RNA replication, and susceptibility to virus infection, we cultured the cells in tubes by rolling [6]. In contrast, to study the effects of tiotropium on nuclear factor kappa-B (NF-κB) activation before RV infection, cells were cultured in tubes under stationary conditions [6]. To examine the effects of rolling, we also studied the effects of tiotropium
on NF-κB subunits in the nuclear extracts of the cells cultured by rolling because cells in the tubes were cultured by rolling after RV infection. Furthermore, acidic endosomes could be observed in the cells living on coverslips in stationary Petri dishes. Therefore, cells used for measuring acidic endosomes were cultured under stationary conditions [6].

Furthermore, to measure virus release from physiological differentiated cells, cells were cultured for 7 days on a filter membrane (Millicell CM inserts, 0.45-μm pore size and 0.6-cm² area, Millipore Products Division, MA) coated with collagen gel (PureCol, INAMED, CA), as described previously [15]. Culture medium (400 μl) was supplied from the basolateral side of the cell sheets through the filter membrane, and the cells were cultured with air-interface methods [15].

Tracheas for cell cultures were obtained after death from 50 patients (age; 70 ± 2 yr; 34 female, 16 male). No patients were complicated with bronchial asthma, while 8 patients were complicated with COPD. Before being hospitalized for the condition that caused death, all of the COPD patients had been treated with tiotropium, but the tiotropium treatment was stopped more than 7 days before death because the patients could not inhale it. Of the 50 patients, 13 were ex-smokers, and 37 had never smoked. This study was approved by the Tohoku University Ethics Committee.

Culture of human embryonic fibroblast cells

Human embryonic fibroblast cells (HFL-III cells, Riken Bio Resource Center Cell Bank, Cell No: RCB0523; Tsukuba, Japan) were cultured in flasks (25 cm² surface area; Becton Dickinson) and were then plated in plastic dishes (MICROTEST™ Tissue Culture Plate, 96 well; Becton Dickinson) or in plastic tubes with round bottoms. The cells were then cultured at 37°C in 5% CO₂–95% air [6].

Viral stocks
Type 14 rhinovirus (RV14) stocks were prepared from a patient with a common cold by infecting human embryonic fibroblast cells, as previously described [16]. We used RV 14 stocks that were passaged 3-5 times.

Detection and titration of viruses

RV14 in supernatant fluids was detected and titrated using the endpoint method [17] by infecting replicate confluent human embryonic fibroblast cells in 96-well plastic dishes with serial 10-fold dilutions of virus-containing supernatant fluids as previously described [6]. The presence of the typical cytopathic effects of RV was monitored in all replicate cells for 7 days (168 h) [6]. On the basis of these data, the TCID₅₀ (tissue culture infective dose) was calculated as previously described [16]. The rates were expressed as TCID₅₀ units/ml/24 h [6].

Quantification of rhinovirus RNA

To quantify RV RNA and ribosomal RNA (18S, rRNA) expression in human tracheal epithelial cells after RV infection, two-step real-time quantitative reverse transcription (RT)-PCR using the Taqman technique (Roche Molecular Diagnostic Systems) was performed with a TaqMan® Gene Expression Master Mix (Applied Biosystems, Bedford, CA, USA) using methods described by Nolan et al. [18], as previously reported [6].

In the first step in quantifying RV RNA, cDNA was transferred from RV RNA using the QuantiTect Reverse Transcription Kit (Qiagen) and the RV reverse primer (5’-CGGACACCCAAAGTAGTCGGT -3’).

In the second step, real-time PCR was performed using cDNA from the RV RNA and the TaqMan® Gene Expression Master Mix. The cDNA sample (2 µl) was mixed with TaqMan Gene Expression Master Mix (10 µl), forward primer (5’-GCACCTCTGTTCAGGAGC-3’; 0.5 µl), reverse primer (5’-
CGGACACCCAAAGTAGTCGGT-3’; 0.5 µl), Taqman probe RV14 (5’-[FAM]CCTTTAACCGTTATCCGCCA[TAMRA]-3’; 0.5 µl), and RNAase-free water (6.5 µl).

To quantify the rRNA, the conversion of rRNA to cDNA and real-time PCR were performed using the same two-step process described above. To quantify rRNA expression, a forward primer (5’-GCACTTCTGTTTCCCAGGAGC-3’), reverse primer (5’-CGGACACCCAAAGTAGTCGGT-3’), and Taqman probe (5’-[FAM]CCTTTAACCGTTATCCGCCA[TAMRA]-3’) were designed for the rRNA.

To obtain quantitative data, the minimum number of PCR cycles required to detect the fluorescent signal was defined as the cycle threshold (Ct) of RV RNA and rRNA from the cells, and quantitative data were obtained as described previously [6].

Viral infection of the epithelial cells

A stock solution of RV14 (100 µl in each tube, 1.0 x 10⁴ TCID₅₀ units/100 µl, 5.0 x 10⁻² TCID₅₀ units/cell) was added to the human tracheal epithelial cells in the tubes [6], except where other virus doses are indicated. After a 1-h incubation at 33°C, the cells were rinsed with phosphate-buffered saline and then fed with fresh medium and cultured at 33°C by rolling, except where other conditions are indicated.

Treatment with tiotropium

To examine the effects of tiotropium, cultured cells from the same donors were treated with either tiotropium (0.1 µM, supplied from Boehringer-Ingelheim, Co., Ltd) or a vehicle (0.001% of 0.01N HCl) from 3 days (72 h) before RV14 infection until the end of the experimental period [6], except where other concentrations or treatment periods are indicated.

To examine the concentration-dependent effects of tiotropium on RV14 infection, cells were treated with tiotropium at concentrations ranging from 10 pM to 10 µM.
Furthermore, to examine the direct interaction of tiotropium with the virus, cells were pretreated with tiotropium (0.1 μM) and tiotropium was removed immediately prior to virus infection. The cells were cultured in the medium in the absence of tiotropium during and after virus infection, and the supernatant fluids were collected after virus infection.

To examine the effects of tiotropium in the cells cultured on filter membranes, culture medium containing tiotropium (0.1 μM) (400 μl) was supplied from the basolateral side of the CM inserts in the dishes [15].

To examine the effects of tiotropium on ICAM-1 mRNA expression in the cells and the concentration of a soluble form of ICAM-1 (sICAM-1) in the supernatant fluids, the cells were pretreated with tiotropium (0.1 μM) from 3 days before RV14 infection.

To examine the concentration-dependent effects of tiotropium on acidic endosomes, cells were treated with tiotropium at concentrations ranging from 1 nM to 10 μM. Likewise, to examine the time-dependent effects of tiotropium on acidic endosomes, the cells were treated with tiotropium (0.1 μM) for time periods ranging from 0 to 3 days (72 h).

Collection of supernatant fluids for measurements

In the cells cultured in the tubes, we measured the time course of viral release using previously described methods [6]. To measure RV14 release during the first 24 h, we used three separate cultures from the same trachea. We collected the supernatant fluids at either 1 h, 12 h, or 24 h after RV14 infection. We also collected supernatant fluids at 3 days (72 h), 5 days (120 h), and 7 days (168 h). At 1 day (24 h), 3 days (72 h), and 5 days (120 h) after infection, supernatant fluids were collected, then fresh medium was replaced, and the cell culture was continued.
Likewise, to examine the effects of tiotropium on the secretion of IL-1β, IL-6, and IL-8, supernatant fluids were collected just before infection and 1 day (24 h), 3 days (72 h), and 5 days (120 h) after RV14 infection.

To measure virus release to the apical side of the cell layers cultured on filter membranes, airway surface liquid (ASL) was collected by washing the apical surface of the layers with 350 μl of medium containing 2% USG as previously described [19]. We collected ASL at 1 day (24 h), 3 days (72 h), 5 days (120 h), and 7 days (168 h) after infection.

**Effects of tiotropium on susceptibility to rhinovirus infection**

The effects of tiotropium on the susceptibility to RV14 infection were evaluated as previously described [6]. Epithelial cells were pretreated with tiotropium (0.1 μM) or vehicle from 3 days (72 h) before infection. The epithelial cells were exposed to serial 10-fold dilutions of RV14 at a dose ranging from $10^1$ to $10^5$ TCID$_{50}$ units/ml in medium, containing tiotropium or vehicle for 1 h at 33°C. After exposure to RV14, fresh medium with no tiotropium was added. The cells in the tubes were then cultured at 33°C by rolling.

We collected the supernatant fluids at 1 day (24 h) and 3 days (72 h) after RV14 infection and measured the RV titers in the supernatant fluids with the human embryonic fibroblast cell assay described above to assess whether infection occurred at each dose ($10^1$, $10^2$, $10^3$, $10^4$, or $10^5$ TCID$_{50}$ units/ml) of RV14 [6].

**Measurement of ICAM-1 expression**

The mRNA of ICAM-1 was examined with two-step real-time RT-PCR analysis using the methods described above (Quantification of rhinovirus RNA) with a forward primer (5’- GCACCTTCTGTTTCCCAGGAGC-3’) and a reverse primer (5’- CGGACACCCAAGTAG TCGGT -3’). A Taqman probe (5’–[FAM]
CCTTAACCGTTATCGCCA [TAMRA–3’) was designed for ICAM-1. The concentration of sICAM-1 in the supernatant fluids was measured with an enzyme immunoassay (EIA) [6].

Measurement of changes in acidic endosomes

The distribution and the fluorescence intensity of acidic endosomes in the cells were measured as previously described with the LysoSensor DND-189 dye (Molecular Probes, Eugene, OR, USA) [6]. Live-cell imaging was performed with the cells on coverslips in Petri dishes, which were observed with a fluorescence microscope (OLYMPUS IX70; OLYMPUS Co. Ltd., Tokyo, Japan). The fluorescence intensity was calculated using a fluorescence image analyzer system (Lumina Vision®; Mitani Co. Ltd., Fukui, Japan). The fluorescence intensity of the acidic endosomes was measured in 100 human tracheal epithelial cells, and the mean value of the fluorescence intensity was expressed as the percentage of the control value compared with the fluorescence intensity of the cells before any treatment.

We studied the effects of a long period of treatment with tiotropium (0.1 μM, 72 h) on acidic endosomes because the cells were pretreated with tiotropium for 3 days (72 h) before RV14 infection, except when we examined the time-dependent effects of tiotropium.

Measurement of cytokine production

We measured IL-1β, IL-6, and IL-8 in supernatant fluids by specific enzyme-linked immunosorbent assays (ELISAs) [6] in duplicate human tracheal epithelial cells in plastic tubes at all timepoints.

NF-kappa B assay
Nuclear extracts from human tracheal epithelial cells were prepared using a TransFactor extraction kit (BD Bioscience/CLONTECH, Mountain View, CA, USA). The presence of the translocated p50, p65, and c-Rel subunits was assayed using a TransFactor Family Colorimetric Kit-NFκB (BD Bioscience/CLONTECH) according to the manufacturer’s instructions, as previously described [6]. The results were expressed as OD, which gives quantitative levels of the NF-κB subunits [6].

**Western blot analysis**

Western blot analysis for the degradation of inhibitory kappa B-α (IκB-α) and the analysis of the amount of phosphorylated IκB-α (p-IκB-α) and β-actin were performed using the methods described previously [6]. Total cellular proteins were obtained by harvesting and lysing human tracheal epithelial cells that were cultured in the presence or absence of tiotropium (0.1 μM or 10 μM, 72 h) before RV14 infection. The blots were rewashed with TTBS, and chemiluminescence was detected using an Amersham ECL Plus western blotting detection kit (GE Healthcare, Waukesha, WI, USA) and a LAS-1000 luminescent image analyzer (Fujifilm, Tokyo, Japan).

**Statistical analysis**

The results are expressed as the mean ± SEM. Statistical analyses were performed using a one-way analysis of variance (ANOVA). Subsequent post-hoc analyses were made using Bonferroni’s method. For all analyses, values of p<0.05 were assumed to be significant. The number of donors (tracheae) from which cultured epithelial cells were used is given as n.
RESULTS

*Effects of tiotropium on rhinovirus infection in human tracheal epithelial cells*

Exposing confluent human tracheal epithelial cell monolayers to RV14 (5.0 x 10^{-2} TCID_{50} units/cell) consistently led to infection. No virus could be detected at 1 h after infection; however RV14 was detected in the culture medium at 12 h, and the viral content progressively increased between 1 and 12 h after infection (Fig. 1a). Evidence of continuous viral production was obtained by demonstrating that each of the supernatant fluids collected during either 12 h to 24 h (1 day), 1 day (24 h) to 3 days (72 h), 3 days (72 h) to 5 days (120 h), or 5 days (120 h) to 7 days (168 h) after infection contained significant levels of RV14 (Fig. 1a). The viral titer levels in the supernatant fluids increased significantly with time for the first 3 days (72 h) (p<0.05 by ANOVA).

Furthermore, in the tracheal cells from subjects whose cells were infected with RV14, the supernatant fluids collected during 1 (24 h) to 3 days (72 h) after infection contained consistent levels of RV14 (4.79 ± 0.25 log TCID_{50} units/ml/24 h, n=50).

Treatment of the cells with tiotropium (0.1 μM) significantly decreased the viral titers of RV14 in supernatant fluids from 12 h after infection compared with the titers in the cells treated with vehicle (0.001% of 0.01N HCl) (Fig. 1a).

RV14 titer levels in the supernatant fluids of the cells from the 13 ex-smokers collected 1 day (24 h) to 3 days (72 h) after infection did not differ from those of the 37 patients who had never smoked (4.81 ± 0.25 log TCID_{50} units/ml/24 h vs. 4.77 ± 0.26 log TCID_{50} units/ml/24 h, respectively, p>0.20).

RV14 titer levels in the supernatant fluids of the cells from the 8 patients complicated with COPD did not differ from those of the 42 patients without COPD (data not shown). Ten patients were complicated with lung diseases, including lung cancer (n=3), idiopathic pulmonary artery hypertension (n=3), idiopathic pulmonary fibrosis (n=2), and pneumonia (n=2). RV14 titer levels in the supernatant fluids of the cells from
these patients did not differ from those of the other 40 patients without lung diseases (data not shown). No virus was detected in the supernatant fluids after infection with ultraviolet (UV)-inactivated RV14 (data not shown).

Treatment with tiotropium (0.1 μM) for 3 days (72 h) did not change viability (99 ± 1% in tiotropium vs. 98 ± 1% in vehicle, n=5, p>0.50), as assessed by the exclusion of trypan blue. Furthermore, until 7 days (168 h) after the start of the cell culture, cells formed confluent sheets in the tubes at the same time point in both the culture medium containing vehicle and the medium containing tiotropium (0.1 μM). The cell number of the confluent sheets cultured in the medium supplemented with tiotropium (0.1 μM) did not differ from the number in the medium supplemented with vehicle (2.1 ± 0.3 x 10^6 of cells/tube in tiotropium vs. 2.2 ± 0.3 x 10^6 of cells/tube in vehicle, n=5, p>0.50).

Treatment with tiotropium (0.1 μM) for 3 days (72 h) did not alter the LDH concentration (33 ± 3 IU/l/24 h in tiotropium vs. 34 ± 3 IU/l/24 h IU/ml in vehicle, n=5, p>0.50) when the LDH concentrations were measured in the supernatant fluids 3 days (72 h) after tiotropium treatment.

Tiotropium inhibited RV14 infection in a concentration-dependent manner. The maximum effect was obtained at 1.0 μM and 10 μM, and the minimum effect was obtained at 33 pM (Fig. 1b).

When the cells were pretreated with tiotropium (0.1 μM, 3 days) and tiotropium was removed just prior to virus infection, RV14 virus titers in the supernatant fluids of the cells pretreated with tiotropium were significantly lower than those of the cells pretreated with vehicle at 1 day (24 h), 3 days (72 h), and 5 days (120 h) after infection (Fig. 1c). By contrast, RV14 titers in the supernatant fluids collected at 7 days (168 h) after infection from the cells pretreated with tiotropium did not differ from those from the cells pretreated with vehicle (Fig. 1c).

When the cells were cultured on filter membranes and exposed to the same concentration of RV14 (100 µl in each filter membrane, 5.0 x 10^2 TCID₅₀ units/cell, 1 h)
as were the cells in the tubes, RV14 was detected in the ASL at 24 h, and the viral content progressively increased between 24 and 72 h after infection (Fig. 1d). Evidence of continuous viral production was obtained by demonstrating that each of the ASLs collected 1 day (24 h) to 3 days (72 h), 3 days (72 h) to 5 days (120 h), or 5 days (120 h) to 7 days (168 h) after infection contained significant levels of RV14 (Fig. 1d). The viral titer levels in the ASL increased significantly with time for the first 3 days (72 h) (p<0.05 by ANOVA). Treatment of the cells with tiotropium (0.1 μM) significantly decreased the viral titers of RV14 in the ASL from 24 h (1 day) after infection compared with the titers in the cells treated with vehicle (0.001% of 0.01N HCl) (Fig. 1d).

The viral titer levels in the ASL from the cells on filter membranes were lower than those in the supernatant fluids of the cells cultured in tubes by rolling (p<0.05, n=3, data not shown). The potency of the inhibitory effects of tiotropium in the cells on filter membranes was similar to that in the cells cultured in tubes (data not shown).

*Effects of tiotropium on viral RNA by real-time RT-PCR*

Further evidence of the inhibitory effects of tiotropium on RV14 RNA replication in human tracheal epithelial cells was provided by real-time quantitative RT-PCR analysis. The RNA extraction was performed at 1 day (24 h) and 3 days (72 h) after RV14 infection. RV14 RNA was consistently observed in the cells from 1 day (24 h) after infection, and the levels increased between 1 day (24 h) and 3 days (72 h) after infection (Fig. 2). In preliminary experiments, the maximum RV RNA replication was observed at 3 days (72 h) after infection (data at 120 h not shown), whereas RV14 RNA was not observed in the cells before infection (data not shown). Tiotropium (0.1 μM) decreased the RV14 RNA levels at 1 day (24 h) and 3 days (72 h) after infection (Fig. 2).

*Effects of tiotropium on susceptibility to rhinovirus infection*
Treatment of the cells with tiotropium (0.1 μM) decreased the susceptibility of the cells to RV14 infection. When viral release was measured using supernatant fluids collected 3 days (72 h) after RV14 infection, the minimum dose of RV14 necessary to cause infection in the cells treated with tiotropium (0.1 μM, 72 h) (3.3 ± 0.2 log TCID₅₀ units/ml, n=5, p<0.05) was significantly higher than that in the cells treated with the vehicle only (0.001% of 0.01N HCl) (2.2 ± 0.2 log TCID₅₀ units/ml, n=5).

**Effects of tiotropium on the expression of ICAM-1**

Tiotropium (0.1 μM, 72 h) reduced baseline ICAM-1 mRNA expression in the cells by approximately 40% compared with the levels in cells treated with the vehicle only (0.001% of 0.01N HCl) before RV14 infection (Fig. 3a). Furthermore, the concentrations of sICAM-1 in the supernatant fluids from the cells treated with tiotropium (0.1 μM) were significantly lower than those from the cells treated with the vehicle only before RV14 infection (Fig. 3b).

**Effects of tiotropium on the acidification of endosomes**

Acidic endosomes in human tracheal epithelial cells were stained green with LysoSensor DND-189 (Figs. 4a-4d), as shown previously [6]. Treatment with the vehicle (0.001% of 0.01N HCl) for 3 days (72 h) did not change the number of acidic endosomes with green fluorescence in the cells (Figs. 4a and 4b). In contrast, treatment with tiotropium (72 h) reduced the number of acidic endosomes with green fluorescence in the cells (0.1 μM in Fig 4c and 10 μM in Fig. 4d).

Likewise, treatment with the vehicle (0.001% of 0.01N HCl) for 3 days (72 h) did not change the fluorescence intensity from the acidic endosomes compared with the intensity in the cells before any treatment (Fig. 5a and 5b). In contrast, treatment with tiotropium reduced the fluorescence intensity from acidic endosomes in the cells.
compared with cells treated with vehicle only (0.001% of 0.01N HCl) or compared with cells before any treatment (Fig. 5a and 5b).

The inhibitory effects of tiotropium on the fluorescence intensity from acidic endosomes were time-dependent, and significant inhibitory effects were observed when the cells were treated with tiotropium (0.1 μM) for 24 h or more (Fig. 5a). The maximum inhibitory effect was obtained when the cells were treated with tiotropium for 3 days (72 h) (Fig. 5a). The inhibitory effects of tiotropium on the fluorescence intensity from acidic endosomes were also dose-dependent. Significant inhibitory effects were observed at 10 nM, and the maximum inhibitory effect was obtained at 10 μM (Fig. 5b).

**Effects of tiotropium on cytokine production**

Tiotropium (0.1 μM) reduced the baseline secretion of IL-1β, IL-6, and IL-8 for 24 h before RV14 infection when compared with the levels in cells treated with vehicle only (0.001 % of 0.01N HCl) (Fig. 6). RV14 infection increased the secretion of IL-1β, IL-6, and IL-8. The maximum secretion was observed at 1 day (24 h) after RV14 infection for IL-6 and IL-8 and at 3 days (72 h) after infection for IL-1β. Tiotropium (0.1 μM) also reduced the RV14 infection-induced secretion of IL-1β, IL-6, and IL-8 when compared with the secretion levels in cells treated with vehicle only (Fig. 6). Furthermore, at a concentration of 33 pM, which corresponds to the plasma concentration after inhalation of 18 μg of tiotropium (clinical dose) [20], tiotropium reduced the RV14 infection-induced secretion of IL-1β (192 ± 5 pg/ml vs. 153 ± 4 pg/ml, 72 h after infection), IL-6 (206 ± 8 pg/ml vs. 146 ± 5 pg/ml, 24 h after infection), and IL-8 (1062 ± 43 pg/ml vs. 961 ± 33 pg/ml, 24 h after infection) when compared with the secretion levels in cells treated with vehicle alone (n=3, p<0.05).

The secretion levels of IL-1β, IL-6, and IL-8 in the supernatant fluids of the cells from the 13 ex-smokers did not differ from the levels of the 37 patients who had never smoked (data not shown). Likewise, the secretion levels of IL-1β, IL-6, and IL-8 in the
supernatant fluids of the cells from the 8 patients complicated with COPD did not differ from the levels of the 42 patients without COPD complications (data not shown).

**Effects on NF-kappa B**

Tiotropium (0.1 μM, 72 h) significantly reduced the amount of the p50, p65, and c-Rel subunits of NF-κB in the nuclear extracts of the cells cultured under stationary conditions before RV14 infection (Figs. 7a-7c). In the cells cultured by rolling in the absence of RV14 infection, tiotropium (0.1 μM, 72 h) also significantly reduced the amount of the p50, p65, and c-Rel subunits of NF-κB in the nuclear extracts. Under conditions with rolling, the amounts of p50, p65, and c-Rel in the nuclear extracts of cells treated with tiotropium (0.1 μM) (0.018 ± 0.001 OD for p50, 0.014 ± 0.001 OD for p65 and 0.008 ± 0.001 OD for c-Rel; p<0.05) were significantly lower than those of the cells treated with a vehicle (0.001% of 0.01N HCl, for 3 days) (0.031 ± 0.002 OD for p50, 0.024 ± 0.001 OD for p65 and 0.017 ± 0.001 OD for c-Rel) in the absence of RV14 infection. Likewise, in cells cultured under stationary conditions before RV14 infection, tiotropium (0.1 μM and 10 μM, 72 h) significantly reduced p-IκB-α levels in the cellular proteins (Fig. 8a and/or 8b). In contrast, tiotropium (0.1 μM and 10 μM, 72 h) significantly increased the amount of IκB-α before infection (Figs. 8a and/or 8c).
DISCUSSION

In the present study, we have shown that the long-acting anti-cholinergic agent tiotropium reduced the titers of a major group rhinovirus, RV14, in the supernatant fluids of primary cultures of human tracheal epithelial cells cultured in tubes [6] and in the ASL of cells cultured on filter membranes with physiological differentiation [15]. Tiotropium also reduced RNA replication of the virus in primary cultures of cells cultured in tubes. Pretreatment with tiotropium reduced the mRNA and protein expression levels of ICAM-1, the receptor for the major group of RVs [10], before RV14 infection. The minimum dose of RV14 necessary to cause infection in cells treated with tiotropium was significantly higher than that in cells treated with the vehicle only. These findings suggest that tiotropium might inhibit RV14 infection partly by reducing the production of its receptor, ICAM-1.

Furthermore, treatment with tiotropium reduced the number and fluorescence intensity of acidic endosomes, from which RV RNA enters the cytoplasm [3, 9], and this reduction was dose- and time-dependent. Inhibition of RNA entry into the cytoplasm by reducing numbers of acidic endosomes may reduce the number of virus virions that enter the cytoplasm. Tiotropium may also inhibit RV14 infection in part by inhibiting RV RNA entry from acidic endosomes into cells.

Human embryonic fibroblast cells did not exhibit any morphological changes that indicate the presence of RV14 when supernatant fluids that were collected 1 h after infection were added to the fibroblast cells. In contrast, supernatant fluids collected 12 h after infection produced morphological changes in the cells, indicating the presence of RV [3, 16, 17]. These findings suggest that supernatant fluids collected 12 h after infection contained significant amounts of RV14 virions that were newly produced after infection, as reported previously [6].

Furthermore, in the tracheal cells from all of the subjects whose cells were infected with RV, the supernatant fluids collected during 1 day (24 h) to 3 days (72 h) after
infection contained consistent levels of RV14. These findings suggest that the tracheal epithelial cells from all of the subjects were constantly infected with RV14.

Maximum serum concentrations of tiotropium have been reported to be 16 ng/L (33 pM) in stable COPD patients given a single 18 μg inhaled dose, which is the clinical dose [20]. In the present study, the inhibitory effects of tiotropium on virus release were concentration-dependent, and significant effects were obtained even at 33 pM. Furthermore, we demonstrated that tiotropium also reduced release of IL-1β, IL-6 and IL-8, even at a low concentration (33 pM). The inhibitory effects of tiotropium on RV14 infection that were observed in the present study are consistent with a previous report that tiotropium inhibits cholinergic contractile responses in human bronchi at concentrations greater than 100 pM [21]. These findings suggest that tiotropium may inhibit RV14 infection and airway inflammation at the doses given safely clinically, and these effects may be relevant to the clinical benefits of tiotropium in the treatment of COPD patients.

In the present study, the amount of virus in the supernatant fluids from cells cultured in tubes by rolling was larger than that in the ASL from physiological differentiated cells [15] that were cultured on filter membranes under stationary conditions. These findings are consistent with those previously reported [3, 6]. The differences in the virus titers may be associated with the characteristics of RV proliferation; culture conditions with rolling may be more suitable for RV proliferation than stationary conditions [3]. Epithelial cells cultured on filter membranes show differentiated features, such as a multilayered structure, increased ion transport and increased protein production [15]. Tiotropium reduced the amount of virus in the ASL from cells cultured on filter membranes with a potency similar to that observed in the supernatant fluids of cells cultured in tubes. These findings suggest that tiotropium may inhibit RV14 infection in airway epithelial cell layers under physiological conditions.
Tiotropium reduced RV14 virus titers in supernatant fluids 1 day (24 h), 3 days (72 h), and 5 days (120 h) after infection when cells were pretreated with tiotropium and tiotropium was removed just prior to virus infection. By contrast, RV14 titers at 7 days after infection in the cells pretreated with tiotropium just prior to infection did not differ from those in the cells pretreated with vehicle. These findings suggest that the inhibitory effects of tiotropium on the cells might continue for 5 days, even after removal of tiotropium from the medium, and that tiotropium may not interact directly with the virus particles.

Neutrophilic inflammation in exacerbations of COPD is suggested to be associated with a variety of mediators, including IL-6, after RV infection [4]. Tiotropium reduces the release of IL-6 and IL-8 induced by RS virus infection in cells of the human epithelial cell line Hep2 [14]. Tiotropium also inhibits the production of pro-inflammatory cytokines and monokines, including IL-6 in mouse lungs [7] and a human bronchial epithelial cell line that was induced by acetylcholine [22]. Furthermore, tiotropium reduces the number of neutrophils in bronchoalveolar lavage fluids in a mouse model of COPD [7] and inhibits neutrophil elastase-induced goblet cell metaplasia in mice [2].

These findings from in vitro, in vivo, and clinical studies suggest that tiotropium may reduce the production and release of inflammatory factors and the accumulation of inflammatory cells in the lung in response to stimuli, including virus infection. Although it is unclear if tiotropium has anti-inflammatory effects in COPD patients [8], these findings suggest the possibility that tiotropium may modulate airway inflammation.

The results in the present study, in which tiotropium reduced RV14 infection-induced production of IL-1β, IL-6, and IL-8, are consistent with those of previous reports. Similar to the inhibitory effects of glucocorticoid, lansoprazole, and procaterol [6, 13], tiotropium may also modulate airway inflammation that is induced by RV infection.
ICAM-1 also plays a vital role in the recruitment and migration of immune effector cells to the sites of local inflammation that are observed in patients with COPD [23]. The inhibitory effects of tiotropium on ICAM-1, as shown in this study, may also be associated with the inhibition exacerbations of COPD [1].

The major group RVs enter the cytoplasm of infected cells after binding to their receptor, ICAM-1 [10]. In the present study, tiotropium reduced ICAM-1 expression in the primary cultures of human tracheal epithelial cells, as shown in the epithelial cell line Hep2 [14]. The inhibitory effects of tiotropium on ICAM-1 expression in human tracheal epithelial cells may be associated with the inhibitory effects of tiotropium on RV14 infection. This phenomenon has been previously reported for the inhibitory effects of various agents, including dexamethasone, erythromycin, the proton pump inhibitor lansoprazole, and the β2 agonist procaterol [6, 13].

The endosomal pH may be regulated by vacuolar H⁺-ATPase [24] and by ion transport across Na⁺/H⁺ exchangers [25]. The vacuolar H⁺-ATPase inhibitor bafilomycin and the Na⁺/H⁺ exchanger inhibitors 5-(N-ethyl-N-isopropyl) amiloride (EIPA) and N''-[3-(Hydroxymethyl)-5-(1H-pyrrol-1-yl) benzoyl] guanidine methanesulfonate (FR168888) increased endosomal pH and inhibited RV14 infection in cultured human tracheal epithelial cells [12]. In the present study, tiotropium increased the endosomal pH, although whether tiotropium inhibits vacuolar H⁺-ATPase or Na⁺/H⁺ exchangers is unknown. Acetylcholine is a physiological stimulus that causes acid secretion in gastric parietal cells through the activation of the H⁺/K⁺-ATPase [26]. A proton pump inhibitor, lansoprazole, inhibits the H⁺/K⁺-ATPase and increases the endosomal pH in human tracheal epithelial cells [13]. Furthermore, a vacuolar H⁺-ATPase inhibitor, bafilomycin A₁, inhibits increases in cytoplasmic pH that are induced by acetylcholine in cultured rabbit non-pigmented ciliary epithelial cells [27]. These findings suggest the possibility that tiotropium has inhibitory effects on the H⁺/K⁺-ATPase and/or the vacuolar H⁺-ATPase in airway epithelial cells.
Acidic endosomes could be observed in the cells living on coverslips in Petri dishes under stationary conditions as reported previously [6]. The cells on the coverslips in Petri dishes could not be cultured with rolling. Therefore, we used cells cultured under stationary conditions to measure acidic endosomes in the present study. We did not examine the effects of tiotropium on acidic endosomes in cells cultured by rolling, the method of culture used after RV14 infection, and our results for the effects of tiotropium on acidic endosomes are thus limited by the need for stationary conditions.

In the present study, we examined the effects of tiotropium in cells under stationary conditions and in cells cultured by rolling and found that tiotropium reduced the amount of the p50, p65, and c-Rel subunits of NF-κB in the nuclear extracts under both conditions. Because the cells were cultured under stationary conditions before RV14 infection and with rolling after infection, these findings suggest that tiotropium inhibits NF-κB activation in cells cultured under either condition. Furthermore, in cells cultured under stationary conditions, tiotropium reduced p-IκB-α levels in the cellular proteins and increased the amount of IκB-α before infection. These findings suggest that tiotropium may inhibit NF-κB activation before and after RV14 infection in the present study.

NF-κB increases the expression of genes encoding ICAM-1 and various pro-inflammatory cytokines [5]. In the present study, tiotropium reduced the expression of ICAM-1 before RV infection and reduced the secretion of pro-inflammatory cytokines in supernatant fluids before and after RV infection. Tiotropium reduced baseline p50, p65, and c-Rel levels of NF-κB before RV infection. Tiotropium also reduced p-IκB-α levels and increased IκB-α levels in the cellular protein pool before RV14 infection. The inhibitory effects of tiotropium on NF-κB activation observed in this study are consistent with those observed in human airway epithelial cells [5, 6]. These findings suggest that tiotropium may reduce the expression of ICAM-1 in cells and the secretion of pro-inflammatory cytokines partly through the reduction of NF-κB activation.
Tiotropium alone did not change cell viability, including cell number, as assessed by the exclusion of trypan blue and the LDH concentrations in the supernatant fluids. However, tiotropium reduced NF-κB activation before RV infection. These findings suggest that reduced cytokine release and ICAM-1 expression may be partly associated with the inhibition of NF-κB activation but not cell injury.

In the present study, RV14 titer levels in the supernatant fluids of the cells from the 8 patients complicated with COPD did not differ from those of the 42 patients without COPD. Likewise, RV14 titer levels in the supernatant fluids of the cells from the 10 patients with lung diseases (lung cancer, idiopathic pulmonary fibrosis, pneumonia, or idiopathic pulmonary artery hypertension) did not differ from the titer levels of the cells from the other 40 patients without lung diseases. Because we isolated the cells from human tracheae after death, the conditions before death, at the time of death, and between the time of death and cell isolation may have masked the characteristic features of the cultured cells as they functioned in the lung diseases in this study. However, further studies are needed to clarify the difference in the magnitude of RV replication in cells from patients, including COPD patients.

The amount of cytokine release after RV infection did not differ between smokers and non-smokers. Conditions before death, at the time of death, and between the time of death and the time of cell isolation may have again masked the cell conditions.

RV infections have been reported to be confined to the upper airways. However, several reports have demonstrated that RV can be cultured from sputum and cells in bronchoalveolar lavage fluids from human subjects after experimental infection [28]. RV can also be detected by RT-PCR in cells in bronchial tissues after inoculation [29]. Furthermore, increased release of RV and cytokines, including IL-6 and IL-8, in tracheal and bronchial epithelial cells from COPD patients has been reported [30], although we could not find differences in RV14 titers in supernatant fluids between COPD patients.
and non-COPD subjects. These findings suggest that the RV14 infection model used in this study with human tracheal epithelial cells could be a valid model.

In summary, this is the first report that the long-acting anti-cholinergic agent tiotropium reduces RV14 titers in supernatant fluids, reduces RV RNA replication in cultured human tracheal epithelial cells, and decreases the susceptibility of the cells to RV14 infection. This effect may occur partly through the reduced expression of ICAM-1, the receptor for the major group of RVs, and a reduction in the number of acidic endosomes from which RV RNA enters the cytoplasm. Tiotropium reduced baseline and RV infection-induced release of IL-1β, IL-6, and IL-8 in the supernatant fluids. Tiotropium may inhibit infection by the major group of RVs and modulate inflammatory responses in the airways after RV infection.
REFERENCES


ACKNOWLEDGMENT

This study was funded by Health, Labour and Welfare Sciences Research Grants for Research on Measures for Intractable Diseases [H20 nanchi ippan 035] from the Japanese Government and was supported by Nippon Boehringer-Ingelheim, Co. Ltd.

Conflict of interest: None
FIGURE LEGENDS

FIGURE 1. a) The time course of viral release in the supernatant fluids of human tracheal epithelial cells obtained at different times after exposure to 5.0 x 10^2 TCID_{50} units/cell RV14 in the presence of tiotropium (0.1 μM) (closed circles) or a vehicle (0.001% of 0.01N HCl) (open circles). The epithelial cells isolated from the same donors were treated with either tiotropium or vehicle from 3 days before infection to the end of the experiments. To examine whether the supernatant fluids contained a significant amount of RV, cytopathic effects on human embryonic fibroblast cells were observed for 7 days (168 h) after placing the supernatant fluids on the fibroblast cells. The rates of change in the RV14 concentration in the supernatant fluids are expressed as TCID_{50} units/ml/24 h. The results are reported as means ± SEM from 6 different tracheae (2 ex-smokers and 4 non-smokers). Significant differences from viral infection alone are indicated by *p<0.05.

b) Concentration-response effects of tiotropium on viral release in supernatant fluids collected between 1 day (24 h) and 3 days (72 h) after infection. The cells were treated with tiotropium (closed circles) or vehicle (Control; 0.001% of 0.01N HCl, open circle) from 3 days (72 h) before RV14 infection until the end of the experimental period, after RV14 infection. The epithelial cells isolated from the same donors were treated with either tiotropium or vehicle. To examine whether the supernatant fluids contained a significant amount of RV, the cytopathic effects on human embryonic fibroblast cells were observed for 7 days (168 h) after placing the supernatant fluids on the fibroblast cells. The rates of change in the RV14 concentration in the supernatant fluids are expressed as TCID_{50}
units/ml/24 h. The results are reported as means ± SEM from either 5 tracheae (at 10 pM, 33 pM, 100 pM), 6 tracheae (at 0.1 μM, 1 μM, 10 μM), or 11 different tracheae (at Control, 1 nM, 10 nM). Significant differences from vehicle alone (Control) are indicated by *p<0.05 and **p<0.01.

c) The time course of viral release in supernatant fluids of human tracheal epithelial cells obtained at different times after RV14 infection in the presence of tiotropium (0.1 μM) (closed circles) or a vehicle (open circles). The cells were pretreated with tiotropium, and tiotropium was removed just prior to virus infection. The results are reported as means ± SEM from 3 different tracheae (1 ex-smoker and 2 non-smokers). Significant differences from viral infection alone are indicated by *p<0.05.

d) The time course of viral release in airway surface liquid (ASL) of human tracheal epithelial cells cultured on filter membranes, obtained at different times after RV14 infection in the presence of tiotropium (0.1 μM) (closed circles) or a vehicle (open circles). The cells were pretreated with tiotropium from 3 days before virus infection to the end of the experiments. The results are reported as means ± SEM from 3 different tracheae (1 ex-smoker and 2 non-smokers). Significant differences from viral infection alone are indicated by *p<0.05.

FIGURE 2. Replication of viral RNA in human tracheal epithelial cells at 1 day (24 h) or 3 days (72 h) after infection with RV14 in the presence of tiotropium (0.1 μM) (RV + Tio) or a vehicle (0.001% of 0.01N HCl) (RV), as detected by real-time quantitative RT-PCR. The epithelial cells isolated from the same donors were treated with either tiotropium or vehicle. The results are
expressed as the relative amount of RNA expression (%) compared to the maximal RV RNA levels at day 3 (72 h) in the cells treated with vehicle, and the results are reported as means ± SEM from 5 samples (1 ex-smoker and 4 non-smokers). Significant differences from treatment with a vehicle (RV) at each time are indicated by *p<0.05.

FIGURE 3. a) The expression of ICAM-1 mRNA before RV14 infection in human tracheal epithelial cells treated with tiotropium (0.1 μM, 72 h, Tiotropium) or a vehicle (0.001% of 0.01N HCl, Control), as detected by real-time quantitative RT-PCR. The epithelial cells isolated from the same donors were treated with either tiotropium or vehicle. ICAM-1 mRNA was normalized to the constitutive expression of ribosomal RNA (rRNA). The expression of ICAM-1 mRNA in the cells treated with vehicle (Control) was set to 1.0. The results are reported as means ± SEM from 5 different tracheae (1 ex-smoker and 4 non-smokers). Significant differences from control values are indicated by *p<0.05.

b) The sICAM-1 concentrations in supernatant fluids before RV14 infection in human tracheal epithelial cells treated with tiotropium (0.1 μM, 72 h, Tiotropium) or a vehicle (0.001% of 0.01N HCl, Control), as detected by enzyme immunoassay. The concentrations of sICAM-1 in the supernatant fluids are expressed as ng/ml. The results are reported as means ± SEM from 5 different tracheae (1 ex-smoker and 4 non-smokers). Significant differences from control values are indicated by *p<0.05.

FIGURE 4. Changes in the distribution of acidic endosomes with green fluorescence in human tracheal epithelial cells before (a) and 3 days (72 h) after treatment
with tiotropium (0.1 μM in c and 10 μM in d) or a vehicle (0.001% of 0.01N HCl) (b). Data are representative of 5 different experiments (2 ex-smokers and 3 non-smokers). (Bar = 100 μm)

FIGURE 5. a) Time course of the effects of tiotropium (0.1 μM) on the fluorescence intensity of acidic endosomes in cells treated for times ranging from 0 (Before) to 3 days (72 h) and the fluorescence intensity in cells treated with a vehicle (0.001% of 0.01N HCl, vehicle) for 3 days (72 h). The results are reported as means ± SEM from 5 different tracheae (2 ex-smokers and 3 non-smokers). Significant differences from before any treatment (Before) are indicated by *p<0.05.

b) Dose-response effects of tiotropium on the fluorescence intensity of acidic endosomes 3 days (72 h) after treatment. The cells were treated with tiotropium or a vehicle (0.001% of 0.01N HCl, vehicle) for 3 days (72 h). The results are reported as means ± SEM from 5 different tracheae (2 ex-smokers and 3 non-smokers). Significant differences from vehicle alone (vehicle) are indicated by *p<0.05 and **p<0.01.

FIGURE 6. a)-c) Time course changes in the release of cytokines into supernatant fluids of human tracheal epithelial cells before and after RV14 infection in the presence of tiotropium (0.1 μM, black bars) or a vehicle (0.001% of 0.01N HCl, white bars). The epithelial cells isolated from the same donors were treated with either tiotropium or vehicle. The concentrations of cytokines in the supernatant fluids are expressed as pg/ml. The results are reported as means ± SEM from 6 different tracheae (1 ex-smokers and 5 non-smokers). Significant differences from values before RV14 infection (time 0) in the
presence of vehicle are indicated by *p<0.05 and **p<0.01. Significant differences from RV14 infection alone (white bars) at each time after infection are indicated by +p<0.05 and ++p<0.01.

FIGURE 7. a)-c) Amount of p50 (a), p65 (b), and c-Rel (c) in the nuclear extracts of human tracheal epithelial cells treated with tiotropium (0.1 μM, Tio) or a vehicle (0.001% of 0.01N HCl, C) for 3 days (72 h) before RV14 infection. The results are expressed as OD and are reported as means ± SEM from 5 different tracheae (2 ex-smokers and 3 non-smokers). Significant differences from control values (C) before RV14 infection are indicated by *p<0.05.

FIGURE 8. a) Representative data on the cytosolic amounts of p-IκB-α, IκB-α or β-actin in human tracheal epithelial cells before RV14 infection in the presence of tiotropium (10 μM, Tio) or a vehicle (0.1% of 0.01N HCl, vehicle). The data are representative of 3 different experiments (1 ex-smoker and 2 non-smokers).

b) and c) The cytosolic amounts of p-IκB-α (b) and IκB-α (c) in cells treated with tiotropium (0.1 μM and 10 μM, Tio) or a vehicle (0.001% of 0.01N HCl, vehicle). The data were obtained by dividing the results in each culture condition by the results for β-actin. The cytosolic amounts of p-IκB-α and IκB-α in the cells treated with vehicle before RV infection (Vehicle) were set to 1.0. The results are means ± SEM from 3 different experiments (1 ex-smoker and 2 non-smokers). Significant differences from control values (vehicle) before RV infection are indicated by *p<0.05 and **p<0.01.
Figure 2

Relative amount of RV-RNA (%)

- RV
- RV + Tio

24 h

72 h

* significant difference
Figure 3
Figure 5

(a) Fluorescence intensity (% pretreatment) for different time points before and after pretreatment with Tiotropium (0.1 μM) for 5 min, 12 h, 24 h, 48 h, and 72 h. The vehicle control is also shown. (b) Fluorescence intensity (% pretreatment) for different concentrations of Tiotropium (-logM) from 9 to 5 compared to the vehicle control.
Figure 7

(a) p50 OD 655nm
(b) p65 OD 655nm
(c) c-Rel OD 655nm

C vs. Tio
Figure 8